In Vivo is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

Brought to you by

Paul Royalty invests $42mm in Guilford, gets royalty rights

Executive Summary

In a deal that will help Guilford Pharmaceuticals fund its acquisition of the cardiovascular drug Aggrastat from Merck & Co., Paul Royalty Funds (PRF)--a unit of Paul Capital Partners set up to acquire royalty and revenue interests of life sciences companies--invested $42mm in the company in exchange for royalties from Guilford's sales of Aggrastat and its brain cancer drug Gliadel.
Deal Industry
  • Biotechnology
  • Pharmaceuticals
Deal Status
  • Final
Deal Type
  • Financing
    • Private Placement

Related Companies